South-East Asia (WHO region) vs Tunisia: HIV-positive TB patients on ART (antiretroviral therapy)
South-East Asia (WHO region)
94.0%
in 2024
Tunisia
100.0%
in 2023
South-East Asia (WHO region) rank
4th
Tunisia rank
1st
HIV-positive TB patients on ART (antiretroviral therapy) over time
- South-East Asia (WHO region)
- Tunisia
How they compare
Tunisia currently reports 100.0% against 94.0% in South-East Asia (WHO region), a difference of 6.0%.
That makes Tunisia's figure about 1.1 times South-East Asia (WHO region)'s.
Across all 19 years both countries report, Tunisia has been ahead every year.
South-East Asia (WHO region) ranks 4th and Tunisia ranks 1st of 11 groups.
Tunisia has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | South-East Asia (WHO region) | Tunisia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 34.1% | 100.0% | 65.9% | Tunisia |
| 2010s | 74.3% | 100.0% | 25.7% | Tunisia |
| 2020s | 91.8% | 100.0% | 8.2% | Tunisia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv-positive tb patients on art (antiretroviral therapy), South-East Asia (WHO region) or Tunisia?
- Tunisia, at 100.0% against 94.0% in South-East Asia (WHO region) as of 2023.
- What is the difference in hiv-positive tb patients on art (antiretroviral therapy) between South-East Asia (WHO region) and Tunisia?
- 6.0%, with Tunisia ahead.
- How many years of comparable data are there for South-East Asia (WHO region) and Tunisia?
- 19 years are reported by both, from 2003 to 2023.
- How do South-East Asia (WHO region) and Tunisia rank globally for hiv-positive tb patients on art (antiretroviral therapy)?
- South-East Asia (WHO region) ranks 4th and Tunisia ranks 1st of 11 groups.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as HIV-positive TB patients on ART (antiretroviral therapy) (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.